Showing results (321-330 of 333) with videos related to
Sort By:
Pageof 34
American Journal of Human Genetics|January 10, 2006
Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlationSeema R Lalani, Arsalan M Safiullah, Susan D Fernbach, et al.Journal of Medicinal Chemistry|July 14, 2000
In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasiaJ C Barrow, P G Nantermet, H G Selnick, et al.Leukemia|December 30, 2015
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cellsO A Guryanova, Y K Lieu, F E Garrett-Bakelman, et al.Cancer Discovery|May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLCihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.Cancer Discovery|July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 InhibitionSheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.Cancer Discovery|July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral MimicryAmish J Patel, Sarah Warda, Jesper L V Maag, et al.Journal of Medicinal Chemistry|May 28, 2004
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitorsMary Beth Young, James C Barrow, Kristen L Glass, et al.Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.Pageof 34